Author details

Full Name

Shiv Srivastava

Affiliation

ORCID

Career Start Year

1990

Papers

194

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37239075	Association of <i>TP53</i> Single Nucleotide Polymorphisms with Prostate Cancer in a Racially Diverse Cohort of Men.	Biomedicines	2023
37945903	Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants.	Nat Genet	2023
37196930	Development and characterization of an ETV1 rabbit monoclonal antibody for the immunohistochemical detection of ETV1 expression in cancer tissue specimens.	J Immunol Methods	2023
36872133	Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry.	Eur Urol	2023
35292633	Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes.	Nat Commun	2022
35622325	Immunoglobulin/T Cell Receptor Capture Strategy for Comprehensive Immunogenetics.	Methods in Molecular Biology	2022
35354846	Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression.	Sci Rep	2022
35781212	Diagnosis of Pancreatic Cancer Using miRNA30e Biosensor.	Interdisciplinary Sciences - Computational Life Sciences	2022
34424321	Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders.	Blood advances	2021
33847515	Prognostic Features of Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy Based on Multiparametric MRI and Immunohistochemistry Analysis of MRI-guided Biopsy Specimens.	Radiology	2021
33473200	Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.	Nat Genet	2021
33575208	Age and Tumor Differentiation-Associated Gene Expression Based Analysis of Non-Familial Prostate Cancers.	Front Oncol	2021
34302010	Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia.	Sci Rep	2021
32930425	African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer.	Int J Cancer	2021
32967771	Prognostic features of Annexin A2 expression in prostate cancer.	Pathology	2021
33398198	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.	Nat Genet	2021
34790292	New Selective Inhibitors of ERG Positive Prostate Cancer: ERGi-USU-6 Salt Derivatives.	ACS Medicinal Chemistry Letters	2021
32842649	Gene Isoforms: A Potential Biomarker and Therapeutic Target in Prostate Cancer.	Biomolecules	2020
32429558	Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression.	Cancers (Basel)	2020
31910880	Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer.	J Transl Med	2020
32064040	Characterization of unique gene splice variants (isoforms and ) from RNA Seq profiling provides novel insights into prognostic evaluation of prostate cancer.	Oncotarget	2020
32409115	A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry.	Eur Urol	2020
32341752	Association of germline genetic variants with <i>TMPRSS2-ERG</i> fusion status in prostate cancer.	Oncotarget	2020
32047232	A novel next generation sequencing approach to improve sarcoma diagnosis.	Mod Pathol	2020
32459607	Inulin as a Delivery Vehicle for Targeting Colon-Specific Cancer.		2020
32856020	Prostate cancer heterogeneity assessment with multi-regional sampling and alignment-free methods.	NAR Genom Bioinform	2020
33287361	Detection of Structural Variants in Circulating Cell-Free DNA from Sarcoma Patients Using Next Generation Sequencing.	Cancers (Basel)	2020
30929837	Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer.	European urology oncology	2019
31798766	Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF-Î² from growth suppressor to growth and metastasis promoter through TMEPAI/PMEPA1 in triple negative breast cancer.	Genes and Cancer	2019
31741711	Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies <i>ERG</i> as the strongest independent predictor of recurrence.	Oncotarget	2019
31741711	Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies <i>ERG</i> as the strongest independent predictor of recurrence.	Oncotarget	2019
31842254	Analysis of <i>PMEPA1</i> Isoforms (<i>a</i> and <i>b</i>) as Selective Inhibitors of Androgen and TGF-Î² Signaling Reveals Distinct Biological and Prognostic Features in Prostate Cancer.	Cancers (Basel)	2019
30542053	Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.	Prostate Cancer Prostatic Dis	2019
31121829	Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors.	International Journal of Molecular Sciences	2019
31013716	A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges.	Int J Mol Sci	2019
31205559	ERG Tumor Type is Less Frequent in High Grade and High Stage Prostate Cancers of Chinese Men.	Journal of Cancer	2019
29690565	Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities.	Int J Mol Sci	2018
28753864	Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.	Eur Urol Focus	2018
28872154	Ethnicity and ERG frequency in prostate cancer.	Nature Reviews Urology	2018
30150711	Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer.	Sci Rep	2018
29712692	Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth.	Cancer Res	2018
28065537	Re: Inherited DNA-repair Gene Mutations in Men with Metastatic Prostate Cancer.		2017
28633309	TMPRSS2:ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences.	Am J Epidemiol	2017
28878398	Erratum: ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development.	Sci Rep	2017
28439080	ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development.	Sci Rep	2017
28607007	Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells.	Mol Cancer Res	2017
29117387	Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry.	J Natl Cancer Inst	2017
29682400	Clinical Validation of a Serum Protein Panel (FLNA, FLNB and KRT19) for Diagnosis of Prostate Cancer.	J Mol Biomark Diagn	2017
28191285	Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag.	Genes Cancer	2016
26723180	Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score.	Urology	2016